Dyspnea

News

Related Video News

No related video news stories found.

Organic Broadcast Project

Related Videos

No related videos found.

ERBITUX(R) Phase 3 BMS-099 Lung Cancer Study Secondary Endpoint Update: Overall Survival Results Announced

Published August 29, 2008, 9:40 am, Centre Daily Times

ImClone Systems Incorporated (NASDAQ: IMCL) today announced overall survival results from BMS CA225-099 (BMS-099), an open-label Phase 3 study of ERBITUX(R) (cetuximab) in combination with a taxane and carboplatin in the first-line treatment of all histological subtypes of advanced non-small cell lung cancer (NSCLC).

Discover News | Full Story


New England Journal Of Medicine Publishes Phase III Results Of VELCADE(R) (Bortezomib) For Injection In Previously ...

Published August 29, 2008, 6:12 am, Medical News Today

Millennium: The Takeda Oncology Company announced the publication of results from the 682 patient, randomized, Phase III VISTA(1) trial in this week's edition of the New England Journal of Medicine.

Discover News | Full Story


Gleevec receives FDA priority review for gastrointestinal stromal tumors after surgery

Published August 27, 2008, 3:12 pm, News-Medical-Net

Novartis has announced that Gleevec (imatinib mesylate) tablets, (known as Glivec (imatinib) outside the US, Canada and Israel), has been granted priority review status by the US Food and Drug Administration (FDA) as the first therapy to be reviewed for use after surgery in kit-positive gastrointestinal stromal tumors (GIST).

Discover News | Full Story


New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously ...

Published August 27, 2008, 2:00 pm, PR Newswire via Yahoo! Finance

Millennium: The Takeda Oncology Company today announced the publication of results from the 682 patient, randomized, Phase III VISTA trial in this week's edition of the New England Journal of Medicine.

Discover News | Full Story


Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After ...

Published August 27, 2008, 4:00 am, PR Newswire via Yahoo! Finance

Novartis announced today that GleevecĀ® tablets* has been granted priority review status by the US Food and Drug Administration as the first therapy to be reviewed for use after surgery in kit-positive gastrointestinal stromal tumors .

Discover News | Full Story



News Directory

Get started fast by using a pre-defined news directory category

Breaking News
and Top Stories
Business
Earnings, Economy, Personal Finance, and Stock Markets
Entertainment
Books, Celebrity, Fashion, Movies, Music, Television, and Theatre
Health
Aging, Diseases, Medical Conditions, Medications, Sexual Health, and Weight Loss
Politics
Congress, Supreme Court, and White House
Science
Animals, Astronomy, Biotechnology, Space, and Weather
Sports
Baseball, Basketball, Boxing, Football, Golf, Hockey, Motor Sports, Soccer, and Tennis
Technology
Communications, Hardware, Internet, Personal Technology, and Software
United States
and Crimes and Trials
World
Africa, Antartica, Asia, Australia, Canada, Europe, Latin America, and Middle East


© Copyright 2005-2006 News Meme, All Rights Reserved | More News | Link Index | OSWD Design

Powered by Odin Assemble 2.5a